Mitotech’s well-balanced management team includes experts in drug development, financial industry, fundamental biological research and start-up management. It is a blend of decades of experience in drug development and of a fresh vision of how science can transform healthcare. Our team has been tested by years of intensive collaborative work, but we are always on a lookout for new talent.
CEO: Natalia Perekhvatova, MS, MBA
Natalia has been leading company’s growth as its Chief Executive Officer/Chief Financial Officer, transforming the company from a drug discovery start-up to a dynamic clinical-stage biotech. Prior to Mitotech she acquired extensive experience in financial and IT infrastructure industries holding senior positions at Citigroup and Amadeus. She received her MBA degree from INSEAD, France and MS degree in Applied Mathematics with honors from the Moscow State University, Russia.
CCO: Lawrence Friedhoff, MD, PhD, FACP
Dr. Friedhoff joined Mitotech as a Chief Clinical Officer and has been shaping company’s pre-clinical and clinical development programs in the U.S. and Europe since then. During his 30-year career in the pharmaceutical industry, he has managed the development of six new products all of which were approved by the FDA. The annual sales of these new products total over $4 billion. His expertise covers planning and managing drug development from early preclinical stage to marketing approval. Before joining Mitotech, Dr. Friedhoff led clinical development at a variety of pharmaceutical and biotechnology companies including Bristol-Myers Squibb, Eisai, Andrx Laboratories and Axovant. His academic career includes positions at Cornell Graduate School of Medical Science and Sloan-Kettering Institute. Dr. Friedhoff holds MD degree from NYU School of Medicine and PhD degree from Columbia University.
CSO: Maxim Skulachev, PhD
Dr. Skulachev is a leading developer of Mitotech’s lead candidate SkQ1 and a proven thought-leader in the biology behind it. He leads company’s drug discovery and drug formulation optimization efforts across therapeutic areas. Having multiple scientific teams under his supervision and collaborating with many more partner laboratories and scientific groups, Dr. Skulachev manages Mitotech’s fundamental research efforts that provide our company with valuable competitive advantage. His extensive academic career has originated from the Moscow State University, Russia, where he received his PhD.
COO: Anton Petrov, PhD, MBA
Anton has been working as Chief Operating Office of Mitotech through all stages of company’s evolution. He has been supervising the operations behind Mitotech's drug development process in the U.S. and EU, concentrating on preclinical and clinical operations. He has been working in biotechnology industry for two decades, having held management positions at several biotech start-ups prior to joining Mitotech. He received his PhD from the University of Southern California and obtained his MBA from INSEAD, France.